What is the first‑line oral antibiotic for non‑purulent cellulitis of the forearm in a healthy adult without MRSA risk?

Best Antibiotic for Non-Purulent Forearm Cellulitis

For a healthy adult with non-purulent cellulitis of the forearm and no MRSA risk factors, prescribe cephalexin 500 mg orally every 6 hours for 5 days—this beta-lactam monotherapy achieves 96% clinical success and is the standard of care. 1

First-Line Oral Beta-Lactam Options

Beta-lactam monotherapy is the definitive treatment for typical non-purulent cellulitis because the primary pathogens are beta-hemolytic streptococci (especially Streptococcus pyogenes) and methicillin-sensitive Staphylococcus aureus (MSSA). 1, 2

Recommended Agents (Choose One):

• Cephalexin 500 mg orally every 6 hours 1
• Dicloxacillin 250-500 mg orally every 6 hours 1
• Amoxicillin 500 mg orally three times daily 1
• Penicillin V 250-500 mg orally four times daily 1

All provide excellent streptococcal and MSSA coverage with equivalent efficacy. 1

Treatment Duration: The 5-Day Rule

Treat for exactly 5 days if clinical improvement occurs (reduced warmth, tenderness, improving erythema, no fever); extend only if symptoms have not improved within this timeframe. 1 High-quality randomized controlled trial evidence demonstrates that 5-day courses are as effective as 10-day courses for uncomplicated cellulitis, with 98% clinical resolution at 14 days and no relapses by 28 days. 1 Traditional 7-14 day regimens are unnecessary and promote antimicrobial resistance. 1

When MRSA Coverage Is NOT Needed

Do not add MRSA-active antibiotics for typical forearm cellulitis. MRSA is an uncommon cause of non-purulent cellulitis even in high-prevalence settings, and adding MRSA coverage provides no benefit in 96% of cases. 1, 3, 4 A landmark randomized controlled trial showed that adding trimethoprim-sulfamethoxazole to cephalexin did not improve outcomes (85% cure vs. 82% cure, p=0.66). 4

When to Add MRSA Coverage (Specific Risk Factors Only)

Add MRSA-active therapy only when any of the following are present:

• Penetrating trauma or injection drug use 1
• Visible purulent drainage or exudate 1, 5
• Known MRSA colonization or prior MRSA infection 1
• Systemic inflammatory response syndrome (fever >38°C, heart rate >90 bpm, respiratory rate >24 breaths/min) 1
• Failure to respond to beta-lactam therapy after 48-72 hours 1

MRSA-Active Regimens (When Indicated):

• Clindamycin 300-450 mg orally every 6 hours (single-agent coverage for both MRSA and streptococci, but use only if local MRSA clindamycin resistance <10%) 1, 5
• Trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily PLUS a beta-lactam (cephalexin or amoxicillin) 1, 5
• Doxycycline 100 mg orally twice daily PLUS a beta-lactam 1, 5

Never use doxycycline or trimethoprim-sulfamethoxazole as monotherapy for typical cellulitis—they lack reliable activity against beta-hemolytic streptococci, the predominant pathogens. 1, 6

Hospitalization Criteria

Admit patients with forearm cellulitis if any of the following are present:

• Systemic inflammatory response syndrome (fever, tachycardia, hypotension, altered mental status) 1
• Signs of necrotizing infection (severe pain out of proportion to exam, skin anesthesia, rapid progression, "wooden-hard" tissue, gas or bullae) 1
• Severe immunocompromise or neutropenia 1
• Failure of outpatient therapy after 24-48 hours 1

Inpatient IV Regimens:

• Without MRSA risk factors: Cefazolin 1-2 g IV every 8 hours 1
• With MRSA risk factors: Vancomycin 15-20 mg/kg IV every 8-12 hours (target trough 15-20 mg/L) 1, 5
• Severe cellulitis with systemic toxicity: Vancomycin PLUS piperacillin-tazobactam 3.375-4.5 g IV every 6 hours 1

Essential Adjunctive Measures

• Elevate the affected arm above heart level for at least 30 minutes three times daily to promote gravity drainage of edema and inflammatory substances 1
• Reassess within 24-48 hours to verify clinical response; treatment failure rates of approximately 21% have been reported with some oral regimens 1
• Treat predisposing conditions such as chronic eczema, venous insufficiency, or lymphedema to reduce recurrence risk 1

Critical Pitfalls to Avoid

• Do not reflexively add MRSA coverage for typical non-purulent cellulitis without the specific risk factors listed above—this overtreats 96% of cases and drives resistance 1, 4
• Do not automatically extend therapy to 7-10 days based on residual erythema alone; extend only if warmth, tenderness, or erythema have not improved after 5 days 1
• Do not delay surgical consultation if signs of necrotizing infection, deep abscess, or systemic toxicity develop 1
• Do not use beta-lactams alone if purulent drainage is present—they lack MRSA activity 5, 6